A multicentre phase 1b study of NG-641, a novel transgene-armed and tumour-selective adenoviral vector, and pembrolizumab as neoadjuvant treatment for squamous cell carcinoma of the head and neck

NG-641 - PsiOxus

Keytruda (pembrolizumab) - Merck (MSD)

https://jitc.bmj.com//content/9/Suppl_2/A467

Christian Ottensmeier 1; Mererid Evans 2; Emma King 3; Ioannis Karydis 4; Tom Lillie 5; David Krige 5; Jenny Lee 5; Matthew Thomas 5; Kevin Harrington 6

Oct 1, 2021